Navigation Links
Pinnacle Biologics Announces Stock Purchase Agreement With MedImmune
Date:6/25/2008

ROCKVILLE, Md., June 26 /PRNewswire/ -- Pinnacle Biologics, a private, full service pharmaceutical and biotech solutions company, today announced that it has entered into a preferred stock purchase transaction with MedImmune, LLC, pursuant to which MedImmune has acquired certain unspecified number of preferred stock shares of Pinnacle Biologics, Inc. The terms of the agreement were not disclosed.

Pinnacle Biologics owns the marketing and distribution rights to MedImmune's Ethyol(R), 50 mg/ml, powder for solution for infusion in Western Europe, Turkey and Israel.

"This is a highpoint for Pinnacle, as it signifies an additional milestone for our company," said Guillermo Herrera, Chairman of the Board of Pinnacle Biologics.

About Pinnacle Biologics

Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.

Website: http://www.pinnaclebiologics.com

COMPANY CONTACT:

James R. Miller, Pinnacle

President & CEO

1 (240) 372-4599


'/>"/>
SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Pinnacle Biologics Announces Contract With Chiltern
2. Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
3. Dermatologists Report Increased Use of Biologics in the Treatment of Psoriasis
4. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
5. QSV Biologics awarded cGMP manufacturing contract by Pfizer Inc.
6. Insmed to Present at CBI Follow-On Biologics Conference
7. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
8. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
11. MedImmune Submits Biologics License Application to FDA for Motavizumab
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017 SomaGenics ... from the NIH to develop RealSeq®-SC (Single Cell), expected ... for profiling small RNAs (including microRNAs) from single cells ... Program highlights the need to accelerate development of approaches ... "New techniques for measuring levels ...
(Date:10/9/2017)... ... ... The award-winning American Farmer television series will feature 3 Bar Biologics in an ... on RFD-TV. , With global population estimates nearing ten billion people by 2050, ... a growing nation. At the same time, many of our valuable resources are becoming ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):